ASCO plc News

MEDIAN Technologies , a leading medical imaging software developer and service provider for oncology clinical trials, announced today its participation in the 2012 ASCO annual conference, to be held next June 1-5, in Chicago, IL, USA.

Genelux Corporation Announces Phase I Data Presentation at 2012 ASCO Annual Meeting of GL-ONC1, Its Oncolytic Virus Lead Product Candidate SAN DIEGO, CA -- -- 05/30/12 -- Genelux Corporation, a privately held, clinical-stage biopharmaceutical company focused on development and commercialization of best-in-class, vaccinia-virus-based oncolytic viral ... (more)

The data relate to the completed Phase 1 clinical trial of GL-ONC1 administered to patients with advanced solid tumors and show preliminary evidence of anti-tumor activity with Stable Disease observed in 33% of patients across a range of cancers.

GE Healthcare, is working to help physicians potentially improve patient care throughout the breast cancer journey through one of the most comprehensive portfolios of technologies in the industry available today.

SCRI Investigators are Authors on 60 Abstracts to be Presented at the American Society of Clinical Oncology Annual Meeting for presentation at the 2012 ASCO Annual Meeting, the premier educational and scientific oncology conference, which takes place June 1-5 in Chicago.

Myrexis is an early-stage pharmaceutical company that focuses on the development of anti-cancer drugs whose shares are trading -41.00 % from their 52-week high .

Without a doubt, Dendreon is one of the most controversial stocks in the market today.

"ASCO annual meeting is a great venue for Western Pharma companies and CROs looking into expanding the geography of their clinical trial programs to meet solution providers such as our company," said Dr.

TAMPA, Fla. & MINNEAPOLIS -- -- Biovest International, Inc. , a majority-owned subsidiary of Accentia Biopharmaceuticals, Inc.

Good morning, almost afternoon. Thanks very much for sticking around for the last session.

NEW YORK -- In case you missed them, here are the top 10 most popular articles and videos on TheStreet today.

The abstracts are now available on the ASCO 2012 website . Claudio Bordignon, MolMed's Chairman and CEO, comments: "This year yet again we had an important number of abstracts accepted at ASCO, including the concept and design of our ongoing cell therapy Phase III trial with TK.

TIVO-1 is the first superiority pivotal study in first-line advanced renal cell carcinoma in which an investigational agent has demonstrated statistically significant and clinically meaningful progression-free survival superiority versus an approved targeted agent in advanced RCC.

WALTHAM, Mass. -- -- ImmunoGen, Inc . , a biotechnology company that develops targeted antibody-based anticancer products, today announced that there will be four presentations at the upcoming 2012 American College of Clinical Oncology Annual Meeting on compounds that utilize the Company's Targeted Antibody Payload technology.

Pharmacyclics, Inc. today reported financial results and recent developments for its fiscal third quarter ended March 31, 2012.

As I peruse the biotech forums and boards trying to ascertain investors' and analysts' opinions on my favorite biotechs, I am amazed with the types of personalities, information and misinformation I come across.

Newswise - BUFFALO, NY - Alex Adjei, MD, PhD, FACP, Senior Vice President of Clinical Research and Katherine Anne Gioia Chair in Cancer Medicine at Roswell Park Cancer Institute , has received the inaugural Drug Development Research Professorship Award from the Conquer Cancer Foundation of the American Society of Clinical Oncology .

Management to host investor conference call featuring Dr. Chawla on Monday, June 4, at 10:00 a.m. Eastern time LOS ANGELES-- --May 7, 2012 - CytRx Corporation , a biopharmaceutical company specializing in oncology, today announced that complete data from the Company's Phase 1b/2 clinical trial with its proprietary doxorubicin tumor-targeting ... (more)

Biovest International, makers of the personalized therapeutic lymphoma vaccine BiovaxID, have announced that data from the company's Phase II mantle cell lymphoma clinical trial will be presented by the National Cancer Institute at the upcoming 2012 American Society of Clinical Oncology Annual Meeting in June .